Mounia Chaoui-Roulleau

Aptanomics SA discovers and develops new drugs in major markets of unmet medical need. Its proprietary discovery engine, based on peptide aptamers, delivers a regular flow of new hits against relevant industrial targets. Aptanomics offers opportunities for drug discovery collaborations leveraging the peptide aptamer technology to identify new druggable sites and screen for small molecule hits. The company was founded by Roger Brent, Pierre Colas and Johm B. Hawken in 2001 and is headquarters in Lyon, France

Funxional Therapeutics Ltd. is a clinical stage pharmaceutical company, which offers drug and therapeutic development programs. It specializes on anti-inflammatory therapies and compounds. The company was founded by David J. Grainger on August 8, 2011 and is headquartered in Cambridge, the United Kingdom.

INSERM Transfert SA is a Venture Capital firm, a subsidiary of Institut National de la Sant? et de la Recherche M?dicale founded in 2000. INSERM Transfert SA is headquartered in Paris, France.

TiGenix NV engages in the research, development, and commercialization of biopharmaceutical products. The firm's portfolio includes allogeneic adipose-derived stem cells and allogeneic cardiac stem cells. It intends to treat Crohn's disease, sepsis, autoimmune disorders, acute myocardial infarction, and chronic cardiovascular indication. The company was founded by Gil Beyen and Frank P. Luyten on February 21, 2000 and is headquartered in Leuven, Belgium.

Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland.

Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.

Prosonix Ltd. engages in the provision of inhaled respiratory medicines. The company was founded by Andre James Bush and David Hipkiss in 2006 and is headquartered in Oxford, the United Kingdom.

Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria.

Millendo Therapeutics SAS provides pharmaceutical research services. It engages in the development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The company was founded by Thierry Abribat, André de Villers, Ezio Ghigo and Aart Jan van der Lely on April 23, 2007 and is headquartered in Ecully, France.

Eye Tech Care SA develops medical devices for non-invasive eye disease treatment. It offers an ultrasound device which offers a non-invasive treatment that utilizes the ultrasound circular cyclo-coagulation procedure that reduces the intraocular pressure in refractory glaucoma. The firm serves the ophthalmology market in France and Europe. The company was founded by Fabrice Romano, Laurent Farcy and Philippe Chapuis in 2008 and is headquartered in Rillieux-la-Pape, France.

DNA Therapeutics SA operates as a clinical stage biopharmaceutical company. It focuses in the research and development of life-saving therapeutics for treatment-resistant cancers. The company was founded by Jian-Sheng Sun and Marie Dutreix in June 2006 and is headquartered in Evry, France.

Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France.

Physio-Assist SAS develops an expertise in bronchial mucus analysis and clearance. The company was founded by Adrien Mithalal on September 17, 2012 and is headquartered in Aix en Provence, France.

Turenne Capital Partenaires SA (Turenne Capital) is a venture capital subsidiary of Turenne Associés SA founded in 1999 by Aymard de Lasteyrie. The firm is headquartered in Paris, France.

Sofimac Innovation SAS is an independent, early-stage venture capital firm which was created in 1998 by Eric Harlé and Didier Moret. Headquartered in Paris, France, Sofimac Innovation manages venture capital funds which provide equity financing for start-ups and early-stage companies in the Information and Communication Technologies (Software, SaaS, Multimedia and Telecom) sector.